A detailed history of Advisor Group Holdings, Inc. transactions in Rhythm Pharmaceuticals, Inc. stock. As of the latest transaction made, Advisor Group Holdings, Inc. holds 668 shares of RYTM stock, worth $37,274. This represents 0.0% of its overall portfolio holdings.

Number of Shares
668
Previous 1,160 42.41%
Holding current value
$37,274
Previous $47,000 27.66%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$40.81 - $55.0 $20,078 - $27,060
-492 Reduced 42.41%
668 $34,000
Q2 2024

Aug 13, 2024

BUY
$35.41 - $44.37 $15,297 - $19,167
432 Added 59.34%
1,160 $47,000
Q1 2024

May 10, 2024

BUY
$39.12 - $52.44 $20,303 - $27,216
519 Added 248.33%
728 $31,000
Q3 2023

Nov 13, 2023

SELL
$15.81 - $27.8 $632 - $1,112
-40 Reduced 16.06%
209 $4,000
Q2 2023

Aug 10, 2023

BUY
$16.32 - $21.15 $652 - $846
40 Added 19.14%
249 $4,000
Q3 2022

Nov 14, 2022

SELL
$4.3 - $30.85 $4 - $30
-1 Reduced 0.48%
209 $5,000
Q1 2022

May 04, 2022

SELL
$6.13 - $12.24 $3,678 - $7,344
-600 Reduced 74.07%
210 $2,000
Q3 2021

Nov 05, 2021

SELL
$11.68 - $20.72 $1,226 - $2,175
-105 Reduced 11.48%
810 $11,000
Q2 2021

Aug 02, 2021

SELL
$18.52 - $22.55 $1,481 - $1,804
-80 Reduced 8.04%
915 $18,000
Q1 2021

May 13, 2021

BUY
$20.25 - $39.49 $911 - $1,777
45 Added 4.74%
995 $21,000
Q4 2020

Feb 10, 2021

BUY
$21.17 - $32.61 $1,587 - $2,445
75 Added 8.57%
950 $28,000
Q3 2020

Nov 12, 2020

BUY
$18.13 - $30.61 $12,237 - $20,661
675 Added 337.5%
875 $19,000
Q1 2020

May 18, 2020

BUY
$13.16 - $22.9 $2,632 - $4,580
200 New
200 $3,000

Others Institutions Holding RYTM

About RHYTHM PHARMACEUTICALS, INC.


  • Ticker RYTM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,720,000
  • Market Cap $3.11B
  • Description
  • Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...
More about RYTM
Track This Portfolio

Track Advisor Group Holdings, Inc. Portfolio

Follow Advisor Group Holdings, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisor Group Holdings, Inc. with notifications on news.